Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia.

Conchon, Monika; Freitas, Carla Maria Boquimpani de Moura; Rego, Maria Aparecida do Carmo; Braga Junior, José Wilson Ramos

Conchon, Monika; Freitas, Carla Maria Boquimpani de Moura; Rego, Maria Aparecida do Carmo; Braga Junior, José Wilson Ramos.

Afiliação

Conchon M; Hematology Service, Hospital Santa Marcelina, São Paulo, SP, Brazil.

Rev Bras Hematol Hemoter ; 33(2): 131-9, 2011.

Article em En | MEDLINE | ID: mdl-23284261

RESUMO

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.

Palavras-chave

Clinical Trial; Drug interactions; Drug resistance, neoplasm; Drug toxicity; Gastrointestinal tract/drug effects; Interferonalpha/administration & dosage; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Piperazines/therapeutic use; Pyrimidines

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Rev Bras Hematol Hemoter Ano de publicação: 2011 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google